Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra (PEN) reported an insider transaction by its President, Shruthi Narayan. On 10/15/2025, 1,294 shares of common stock were withheld at $252.61 per share to satisfy tax withholding obligations tied to the vesting of restricted stock units.
Following the transaction, the reporting person beneficially owned 26,961 shares directly. The filing notes that a portion of these shares is subject to vesting.
Penumbra (PEN) director Harpreet Grewal reported a sale of common stock. On 10/02/2025, the reporting person sold 186 shares at $248.61 per share under a Rule 10b5-1 trading plan. Following the transaction, the filer directly beneficially owned 8,702 shares. A portion of these shares is subject to vesting.
Johanna Roberts, EVP, General Counsel & Secretary of Penumbra Inc (PEN), reported multiple open-market sales executed 10/01/2025 under a Rule 10b5-1 trading plan. The transactions total 600 shares sold in separate blocks at weighted-average prices reported per block (ranging across the disclosures). Following these disposals, Ms. Roberts' beneficial ownership is reported as 64,257 shares. The Form 4 is signed and dated 10/03/2025. The filing notes that a portion of the shares sold were subject to vesting and that the filer will provide trade-level details upon request.
Penumbra Inc. (PEN) director Thomas C. Wilder reported a sale of 186 shares of common stock on 10/01/2025 at a price of $253.93 per share. The filing states the sale was executed under the reporting person’s Rule 10b5-1 trading plan. After the sale the report shows the reporting person beneficially owns 186 shares directly and 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006. The filing also notes that a portion of the reported shares are subject to vesting.
The Form 4 was signed by an attorney-in-fact on behalf of Mr. Wilder on 10/03/2025. No options, derivative transactions, earnings figures, or other corporate actions are disclosed in this form; it records a single small open-market sale and the current direct and indirect holdings disclosed by the reporting person.
Form 144 filed for Penumbra, Inc. (PEN) reports a proposed sale of 186 shares of Common Stock through Fidelity Brokerage Services LLC (Boston, MA) with an aggregate market value of $46,241.46 and an approximate sale date of 10/02/2025. The shares were acquired as a stock award from Penumbra, Inc. on 06/30/2025. The filer also reported a sale of 186 shares on 09/02/2025 with gross proceeds of $50,627.34. The filing names the seller as Grewal Harpreet (c/o Penumbra).
Form 144 notice for Penumbra, Inc. (PEN) reporting proposed sale of common stock. The filing shows 1,800 shares to be sold through J.P. Morgan Securities LLC with an aggregate market value of 455,796, and the approximate sale date listed as 10/01/2025 on the NYSE. The shares were acquired on 12/28/2022 by option exercise and paid in cash. The filer recorded prior sales in the past three months: 600 shares on 08/11/2025 for 143,361.60 and 600 shares on 09/02/2025 for 162,345.63. The filing includes a representation that the seller does not possess undisclosed material adverse information.
Penumbra, Inc. (PEN) filing under Rule 144 notifies the market that a person for whose account securities are being sold intends to sell 186 shares of common stock through Morgan Stanley Smith Barney LLC on or about 10/01/2025. The filing lists the aggregate market value of the shares to be sold as $47,230.98 based on the reported market price, and shows total shares outstanding of 38,999,129. The 186 shares were acquired as restricted stock from the issuer on 09/30/2025, with payment not applicable. The filer also reported a prior sale on 08/12/2025 of 372 shares that generated gross proceeds of $89,339.52. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Pursuant to a Form 4, Penumbra Inc. director and officer Shruthi Narayan was granted 9,170 restricted stock units (RSUs) on 09/15/2025 under the companys Amended and Restated 2014 Equity Incentive Plan. The RSUs vest 25% on each annual anniversary beginning 09/15/2026, subject to continued service. Following the grant, the reporting persons beneficial ownership is reported as 28,255 shares, with a portion of those shares subject to vesting.
PEN Form 3: Shruthi Narayan reported ownership of 19,085 shares of Penumbra Inc common stock, filed as an initial SEC Form 3 reporting a relationship as President and officer. The filing notes that a portion of the shares are subject to vesting. The Form 3 was executed by an attorney-in-fact and dated 09/16/2025 for an event on 09/01/2025, with a remark that the filing was late due to administrative oversight.
Harpreet Grewal, a director of Penumbra, Inc. (PEN), reported a sale of 186 shares of Penumbra common stock on 09/02/2025 at a reported price of $272.19 per share. After the transaction, the reporting person beneficially owned 8,888 shares, noting that a portion of those shares remains subject to vesting.
The filing states the sales were executed under the reporting person’s Rule 10b5-1 trading plan. The Form 4 was signed by an attorney-in-fact on behalf of Harpreet Grewal on 09/04/2025. No options, derivative transactions, or additional material details are disclosed in this filing.